Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease

Introduction: Interstitial lung disease (ILD) is the most frequent cause of drug-related mortality from EGFR tyrosine kinase inhibitors (TKIs). Yet, for patients with symptomatic osimertinib-induced ILD, the risk of recurrent ILD associated with EGFR TKI rechallenge, either with osimertinib or anoth...

Full description

Bibliographic Details

Published in:	JTO Clinical and Research Reports
Main Authors:	Molly S.C. Li, M.B.B.S., Kirsty W.C. Lee, MBChB, Kevin K.S. Mok, MBChB, Herbert H.F. Loong, M.B.B.S., K.C. Lam, MBChB, Florence S.T. Mok, M.B.B.S., Landon L. Chan, MBChB, Y.M. Lau, M.B.B.S., K.P. Chan, MBChB, Joyce T.Y. Ng, MBChB, Wesley K.Y. Wong, M.B.B.S., Benjamin H.W. Lam, M.B.B.S., Allen C.C. Chen, BM, Matthew M.P. Lee, MBChB, Olivia H. Chen, MD, PhD, Tony S.K. Mok, MD
Format:	Article
Language:	English
Published:	Elsevier 2024-04-01
Subjects:	Epidermal growth factor receptor Interstitial lung disease Osimertinib Erlotinib Rechallenge
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364324000183